Author: Editor

Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer Institute and Medical Director of the Case Comprehensive Cancer Center Clinical Research Office at Cleveland Clinic. In this audio, he speaks about the EHA 2022 abstract MOMENTUM: Phase 3 randomized study of Momelotinib (MMB) versus Danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a jak inhibitor. Outline History MMB, a new oral ACVR1/ALK2 and JAK1/2 inhibitor, demonstrated clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. Targets This pivotal…

Momelotinib Shows Promising JAK and ALK2 Inhabitation in Patients With Anemic Myelofibrosis: MOMENTUM Study It’s my pleasure today to discuss with you the results of the MOMENTUM study as presented at EHA 2022. The MOMENTUM study is an incredibly important study in the development of a drug called Momelotinib, a JAK inhibitor that differentiates itself from other inhibitors that are already approved for the treatment of patients with myelofibrosis. What Effects Did Momelotinib Have on ACVR1? A key off-target effect on a molecule called ACVR1, also known as ALK2, It does have the kind of canonical JAK inhibition of JAK2…

Professor Peter Hillmen, MD, he leads the Experimental Haematology section in LICAP and the Translational Haematology Research group. He is a Professor of Experimental Haematology and Honorary Consultant Haematologist at Leeds Teaching Hospitals NHS Trust at University of Leeds. In this audio, he speaks about the EHA 2022 Abstract – The Combination Of Ibrutinib Plus Venetoclax Results In A High Rate Of Mrd Negativity In Previously Untreated Cll: The Results Of The Planned Interim Analysis Of The Phase III Ncri FLAIR Trial. History Ibrutinib (I) and venetoclax (V) both enhance CLL outcomes. I rarely eliminates measurable residual disease (MRD), whereas…

So, I presented the interim analysis of the second part of the FLARE trial, which is a randomized phase 3 trial in previous stances, CLL patients which the total trial we recruit just under 1500 patient. What we presented here was the first interim analysis of comparison of Ibrutinib (I) and venetoclax (V) compared to Ibrutinib (I) monotherapy where half the patients had reached 2 years. That was 2,274 patients randomized. So, we analyze over five total that comparison and setting MRD. First of all, we showed that the treatment well tolerated, there were no. Significant tissues with adding the…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this audio, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Backstory: Early-onset pancreatic cancer (EOPC) is uncommon. It is unknown if the incidence of EOPC is increasing or how these patients are being treated. Methodology: We used SEER 2004-2016 to conduct a retrospective population-based investigation. We looked at the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 patients, as well as treatment patterns in 7307 patients (excluding neuroendocrine tumors) under…

Dana B Cardin, MD, MSCI, Associate Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University Medical Center. In this video, she speaks about the Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.  Observation – Origins: Early-onset pancreatic cancer (EOPC) is a rare occurrence. It is unknown whether the prevalence of EOPC is increasing or how these patients are being treated. Methodologies: We used SEER 2004-2016 to conduct a retrospective, population-based analysis. We looked examined the annual age-adjusted incidence rate (AAIR), stage at presentation, and race/ethnicity of 7802 individuals, as well as treatment patterns in 7307 patients…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this audio, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Brief Overview: Patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) against placebo in this two-part experiment. In a double-blind design, Part 1 participants will be randomly randomized to either pembrolizumab or…

Professor Georgina V. Long, MD, PhD, FRACP, Chair of Melanoma Medical Oncology &Translational Research, Translational Node, Faculty of Medicine and Health at The University of Sydney. In this video, she speaks about the ASCO 2022 Abstract – Distant Metastasis-Free Survival With Pembrolizumab Versus Placebo As Adjuvant Therapy In Stage IIB Or IIC Melanoma: The Phase 3 KEYNOTE-716 Study. Synopsis: In this two-part trial, patients with surgically resected high-risk Stage II melanoma will be compared to the safety and efficacy of pembrolizumab (MK-3475) versus placebo. Part 1 participants will be randomly assigned to either pembrolizumab or placebo in a double-blind design…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this audio, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data. Brief Overview: The FLEX Registry will be a large-scale population-based prospective registry. All patients with stage I to III breast cancer who have MammaPrint® and BluePrint testing on a primary breast tumor are eligible to participate in the FLEX Registry, which is designed to allow for additional study arms…

Cynthia X. Ma, MD, Professor, Department of Medicine, Oncology Division of Medial Oncology of Washington University School of Medicine. In this video, she speaks about the ASCO 2022 Abstract – FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.   Synopsis: The FLEX Registry will be set up as a large-scale, population-based prospective registry. All patients with stage I to III breast cancer who obtain MammaPrint® and BluePrint testing on a primary breast tumor are eligible to join the FLEX Registry, which is designed to allow for additional…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this audio, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this video, she speaks about the ASCO 2022 Abstract –  Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study). Synopsis: This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery…

Charles Ricordel, MD, PhD, Thoracic Oncologist at CHU de Rennes. In this audio, he speaks about the ASCO 2022 Abstract Abstract 9039: Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with NSQ NSCLC expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Summary: The study duration for an individual patient will begin with the signing of the informed consent and will include a screening period of up to 4 weeks (28 days), a treatment period and an end-of-treatment visit around 30 days after the last administration of study drug, and at least one follow-up visit after the end-of-treatment…

CEACAM5: Safety and Efficacy Outcome in Long-term Treatment with SAR408701 in Pts with NSQ NSCLC Prof Charles Ricordel By Professor Charles Ricordel As many of you may know, antibody drug conjugates are generating a lot of hype right now in the oncology field, and RFT-Sign is a novel antibody drug conjugate that selectively targets CEACAM5. CEACAM5 (Carcinoembryonic antigen-related cell adhesion molecule 5) is a membrane protein that is usually expressed in several epithelial tumor types and might be highly expressed in approximately 25% of non-squamous non-small cell lung cancers. This compound comprises a humanized monoclonal antibody drug conjugates linked to…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this Audio, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology division. He is the associate director of clinical research of the USC Norris Comprehensive Cancer Center, is chair of the GI Oncology Program and is the co-director of the Colorectal Center. He also serves as the scientific director of the Cancer Genetics Unit. In this video, he speaks about the ASCO 2022 Abstract Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. Origins: Monoamine oxidases (MAOs), which…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this audio, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen.  Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Erika Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute. In this video, she speaks about the Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen. Enhertu (trastuzumab deruxtecan) has been approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen, either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have experienced disease recurrence during or within six months of completing therapy. AstraZeneca and…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Jonathan Zager, MD, Chief Academic Officer, Chair, USF Department of Oncologic Sciences at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). Synopsis: Patients with melanoma that has progressed from the eye to the liver will be evaluated in this study: Patients in the trial will be given Melphalan/HDS treatments up to a total of six times and will be monitored until death. This study will assess the treatment’s safety and effectiveness in terms of how…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this audio, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy. Origins: The presence of circulating tumor DNA (ctDNA) in patients (pts) after surgery indicates the presence of minimal/molecular residual disease (MRD) and a near-certain likelihood of disease recurrence. Because the likelihood of recurrence is considerable and therapeutic intervention may provide clinical benefit to patients, therapeutic techniques to treat MRD following…

Trevor M. Feinstein, MD, Oncologist, Hematologist at Piedmont Cancer Institute. In this audio, he speaks about the ASCO 2022 Abstract – DUBLIN-3 results on quality of life (QoL) in second/third-line EGFR-wild type NSCLC patients (pts) receiving docetaxel (Doc) with or without plinabulin (Plin) using the validated EORTC QLQ C30 and QLQ LC13 questionnaires. Synopsis: Lung cancer is the biggest cause of cancer-related death globally. In 2018, there were a projected 2.09 million new cases and 1.76 million deaths worldwide, according to the World Health Organization’s Global Cancer Observatory (GLOBOCAN, 2018, Fact Sheet N039). China has a relatively high incidence and…

Plinabulin Improved OS and lower Toxicity in NSCLC EGFR Wild Type The DUBLIN-3 was a randomized phase III trial from BeyondSprings Pharmaceuticals in non-small cell lung cancer. It looked at an advanced non-small cell lung cancer, EGFR wild type. And I was looking at second and third-line treatment. Patients had to progress through at least one line of therapy, but two lines of progression were okay. And patients had to have been exposed to platinum-based therapy. The randomized clinical trial was pretty broad in that it took patients with an ECOG performance status of 2 or better, and they had…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this audio, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract – Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo). Overview: The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo Severe neutropenia is…

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this audio, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Debra A. Patt, MD, Ph.D., MBA, FASCO, is a practicing oncologist and breast cancer specialist in Austin, Texas, and an executive vice president of Texas Oncology with responsibilities in healthcare policy and strategic initiatives. She is an active leader in breast cancer and research in healthcare informatics. In this video, she speaks about the ASCO 2022 Abstract – Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this audio, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Ping Ye, Ph.D., a senior data scientist for the U.S. Oncology Network, and McKesson. In this video, she speaks about the ASCO 2022 Abstract – The initial outcome of deploying a mortality prediction tool at community oncology practices.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Mark T. Fleming, MD is a board-certified medical oncologist. He earned his B.A. from the famous University of Pennsylvania in Philadelphia and his M.D. from the Medical University of Ohio. Dr. Fleming did his residency and Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. He later became a member of Virginia Oncology Associates (VOA). In this video, he speaks about the ASCO Abstract – The impact of diversity, equity, and inclusion training in an independent community oncology practice.

Audio: So I’m Dr. Gabriel Chiosis. I’m a professor and member at Sloan-Kettering Cancer Center and I’m going to discuss today our work or an overview first of our approach to treatment which is to target 1330 interaction networks rather than a protein or an interact or the interaction of two proteins as generally or at least historically we think about therapy, and the paper I was invited to discuss is it’s a protocol we published recently our cells…Read Full Transcript Here Gabriela Chiosis, Ph.D., Researcher at Memorial Sloan Kettering Cancer Center. In this video, she speaks a Gabriela Chiosis,…

Protocol Synthesis of 124I-labeled epichaperome probes and assessment in visualizing pathologic protein-protein interaction networks I’m going to discuss today our work or an overview first of our approach to treatment, which is to target 1313 interaction, rather than a protein or an Interact or interaction of 2 proteins as generally or at least historically we think about therapy. And the paper I was invited to discuss is it’s a protocol we published recently. In cancer cells SAR protocols, and it’s called Synthesis of Labeled Epichaperome Probes and assessment in visualizing pathologic protein interaction networks in tumor-bearing mice. Understanding Epichaperome Probes…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt Cancer Center.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. In this video, he speaks to us about the ASCO 2022 Abstract – Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D. Overview: The goal of this study is to determine the safety and tolerability of the following combinations, as well as to establish a preliminary recommended Phase…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In this video, she speaks about the ASCO 2022 Abstract – Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Synopsis: This phase II trial investigates the side effects and optimal dose of capecitabine when combined with pembrolizumab and bevacizumab, as well as how well they work in treating patients with microsatellite stable colorectal cancer that has spread to nearby tissues or lymph nodes, has spread to other parts of the body, or…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Abhishek Tripathi, MD, Assistant Professor of Medicine in the section of Hematology/Oncology at the University Of Oklahoma Health Sciences Center. In this video, he speaks about the ASCO 2022 Abstract – Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. Overview: Reasoning: Prostate cancer cells can proliferate in response to androgens. Androgen ablation therapy has the potential to prevent the adrenal glands from producing androgens. Chemotherapy drugs, such as docetaxel, function in different ways to inhibit tumor cell growth, either by killing the cells or by…

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Bijal Shah, MD, MS, is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3. Synopsis: The major goals of this trial are to assess the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Robert Ferguson, Ph.D., Biobehavioral Cancer Control Program at UPMC Hillman Cancer Center and the University of Pittsburgh School of Medicine. In this video, he speaks about the ASCO 2022 Abstract – Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: A model for remote clinical trial participation. Synopsis: The overarching goal of this experiment is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT), in treating chemotherapy-related cognitive impairment in breast cancer survivors (male or female). A multi-center, multi-clinician randomized control trial is being conducted (MAAT vs. supportive therapy attention control condition). This trial will also…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Ruben Mesa, MD, FACP, Executive Director of the Mays Cancer Center, home to UT Health San Antonio, MD Anderson Cancer Center. In this video, he speaks about the ASCO 2022 Abstract – MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. Origins: MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, shown clinical activity in the SIMPLIFY trials for MF symptoms, RBC transfusion requirements (anemia), and spleen volume. This pivotal phase 3 research compared MMB to DAN on major symptom, anemia, and spleen volume endpoints at 24…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Richard Woodman, MD Chief Clinical Officer, Oncology Business Group at Eisai, Inc.. In this video, he speaks about the ASCO 2022 Abstract – Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician’s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 (309). Origins: In the multicenter, open-label, randomized, phase 3 Study 309/KEYNOTE-775, LEN + pembro demonstrated significant PFS and overall survival advantages, as well as a higher objective response rate compared to TPC in patients with aEC after systemic platinum-based treatment (Makker 2022,…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…

Rebecca S. Kristeleit, MD, Ph.D., FRCP, specialises in the treatment of gynaecological cancers including cervical, endometrial and ovarian cancer. She also has specialist expertise in novel therapies and molecular testing for gynaecological cancer and has led or been involved in a number of successful new drug applications including rucaparib, lurbinectedin, and dostarlimab. Dr Kristeleit joined Guy’s and St Thomas’ NHS Foundation Trust from UCL in early 2020 to lead the expansion of clinical and translational research in gynaecological cancer and to continue her research with the NIHR Guy’s Clinical Research Facility. She currently leads a large portfolio of Phase I-III…